[Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer].
Pegylated liposomal doxorubicin is considered as one of the treatment options proposed nowadays for recurrent ovarian cancer patients. The aim of this study was to evaluate toxicity profile and effectiveness of this treatment in patients with recurrent ovarian cancer. Thirteen patients with recurrent epithelial ovarian carcinoma were treated by pegylated liposomal doxorubicin of 50 mg/m2 dose in 4-week courses. No serious hematological toxicity was observed. Only one patient showed grade 2 hand-foot syndrome at the 5-7th course, and she had to switch to another therapy. Progression-free interval (PFI) was calculated by GraphPad Prism (version 2.0) program. Two of the 13 patients (15%) showed complete response for 6 months, and 2 patients had partial response (15%). Median PFI was calculated as 2 months in all patients. Pegylated liposomal doxorubicin therapy can be administered with little toxicity in this subset of patients. The PFI is similar to data in the literature (an average of 4 months) in case of excluding data of the incurable patients with very advanced disease who could receive only 1-2 courses of chemotherapy.